Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is a poorly differentiated neuroendocrine carcinoma that cannot be surgically removed and has spread locally or to other parts of your body
- You've completed exactly one cycle of platinum-based chemotherapy plus etoposide within 28 days before joining the study
- Your tumor tissue shows high DLL3 expression (confirmed by a specific lab test on your archived tumor sample)
- You have an ECOG performance status of 0 or 1 (able to care for yourself with minimal limitation)
- You haven't had previous treatment with DLL3-targeting drugs or immunotherapy during your first chemotherapy cycle
- Any side effects from previous treatments have mostly resolved or are manageable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with a rare type of lung cancer called large-cell neuroendocrine carcinoma (LCNEC). It is for those with advanced cancer that can't be cured, and who have just started standard chemotherapy. The drug is given after one cycle of chemo and may help control the cancer.
This study tests a new combination of two investigational drugs, obrixtamig and ZL-1310, for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
This trial tests a new drug (LBL-024) combined with standard chemotherapy for people with advanced EP-NEC, a rare type of neuroendocrine tumor. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy for people with neuroendocrine carcinoma that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
Hear when a new Extrapulmonary Neuroendocrine Cancer (epNEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.